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Epidemiology and Outcomes of 
Bloodstream Infections in Patients With 
Solid Tumors in a Central American 
Population at Mexico Hospital, San Jose, 
Costa Rica
INTRODUCTION
According to the World Health Organization, 
cancer is a leading cause of death worldwide, with 
approximately 14 million new cases annually.1 
Patients with cancer often experience several 
types of complications during their treatments, 
including bloodstream infections (BSIs), which 
are a common cause of morbidity and mortality.2 
Most of the published data on BSIs in patients 
with cancer are from patients with hematologic 
malignancies3; information is scarce on BSIs in 
solid tumors worldwide and even less is available 
for patients in Latin America.4 We conducted a 
retrospective study to evaluate the epidemiologic 
profile and mortality of patients with solid tumors 
who had BSIs and had been admitted to Mexico 
Hospital. To the best of our knowledge, this is 
the first study that describes the current epi-
demiologic situation in Costa Rica and Central 
America.
METHODS
This is a retrospective study conducted at Mexico 
Hospital in San Jose, Costa Rica. We included 
all hospitalized patients with solid tumors who 
had BSIs who were entered into our infectious 
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disease database from January 1, 2012, to 
December 31, 2014. Patients with hematologic 
malignancies were excluded. We analyzed the 
episodes of BSIs according to demographic 
characteristics, microorganism, antimicrobial 
sensitivity, tumor type, and the presence of a 
central venous catheter (CVC). This study was 
approved by the local ethics committee.
Centers for Disease Control and Prevention crite-
ria for defining infections were used,5,6 as well as 
the Third International Consensus definitions for 
sepsis and septic shock (Sepsis-3).7
BSI was defined as the presence of a microor-
ganism in the blood, isolated by at least one pos-
itive blood culture that must have occurred close 
to or concomitant with a clinically or laboratory- 
proven site of infection. For a definitive diag-
nosis of intravascular catheter-related BSIs, the 
same microorganism was required to be isolated 
from at least one percutaneous blood culture of 
the intravascular catheter according to the up-
dated Infectious Diseases Society of America 
clinical practice guidelines for the diagnosis and 
management of intravascular catheter-related 
infections.8
Blood samples were inoculated into BacT/ALERT 
FA (bioMérieux, Durham, NC) culture bottles and 
incubated in a BacT/ALERT 3D automated con-
tinuous monitoring system until microbial growth 
became evident or for 6 days. Bacteria were 
identified and antibiotic susceptibility was ob-
tained by using the automated Vitek 2 System 
(bioMérieux). Clinical and Laboratory Standards 
Institute breakpoints and rules were used to de-
termine antimicrobial susceptibility.9 The antibi-
otics used for antimicrobial susceptibility testing 
for gram-negative bacilli (GNB) were amikacin, 
nalidixic acid, ampicillin/sulbactam, cefalotin, 
cefotaxime, ceftazidime, ciprofloxacin, gentami-
cin, piperacillin/tazobactam, nitrofurantoin, and 
trimethroprim/sulfamethoxazole. Those used for 
gram-positive bacilli were ampicillin, ciprofloxa-
cin, levofloxacin, linezolid, minocycline, nitrofu-
rantoin, teicoplanin, tetracycline, trimethroprim/
sulfamethoxazole, and vancomycin.
Statistical Analysis
Because of the retrospective nature of this study, 
all patients with solid tumors who had BSIs 
were included; during the observational time 
period, neither prespecified sample sizes nor pre- 
established hypotheses were available for evalu-
ation. Categorical variables are presented as per-
centages and were compared by the χ2 test when 
appropriate. Continuous variables are presented 
as the mean ± standard deviation. Mortality rate 
was defined as the number of all causes of death 
within 30 days after the date of documented BSI 
divided by the total number of BSIs in the same 
period. Data were analyzed by using SPSS for 
Mac version 20.0 (SPSS, Chicago, IL).
RESULTS
We used our biostatistical database to review 
1,210 patients who were admitted to the Mexico 
Hospital and were diagnosed with malignant 
solid tumors from January 1 to December 31, 
2012. One hundred sixty-four episodes of BSIs 
were adequately documented, and 14% of hos-
pitalized patients with solid tumors experienced 
at least one episode of BSI. The annual distri-
bution is summarized in Table 1. The median 
age was 57.9 years (range, 15 to 88 years). One 
hundred four cases (63%) of BSIs occurred 
in males, and 33 patients (20%) had febrile 
neutropenia.
Table 2 shows the distribution by year of BSIs ac-
cording to microorganism. A statistically significant 
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Table 1. BSIs in Patients with Malignant Solid Tumors Admitted to Mexico Hospital, 
San Jose, Costa Rica
Year
No. of  
Hospitalized 
Patients No. of BSIs
Episodes of 
BSIs in Patients 
With Febrile 
Neutropenia Yearly BSIs 
(%)No. %
2012 371 47 8 17 12
2013 353 56 14 25 16
2014 486 61 11 17 13
Total 1,210 164 33 20 14
Abbreviation: BSI, bloodstream infection.
Table 2. Distribution of Causative Organisms of All Episodes of BSIs by Year
Year
Microorganism
Total
Gram-Negative Bacilli Gram-Positive Cocci
No. of  
Episodes %
No. of  
Episodes %
2012 32 68 15 32 47
2013 50 89 6 11 56
2014 46 75 15 25 61
Total 128 78 36 22 164
NOTE. χ2, 7.09.
Abbreviation: BSI, bloodstream infection.
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predominance of GNB over gram-positive cocci 
(GPC) was found (78% v 22%; χ2 P = .029). 
Overall, the most frequent GNB were Escherichia 
coli (21.3%), Klebsiella pneumoniae (21.3%), 
and Pseudomonas aeruginosa (15.2%). The most 
frequent gram-positive organisms were Staph-
ylococcus aureus (9.8%), Staphyloccocus epi-
dermidis (5.5%), and all Streptococci species 
together (3%). Among neutropenic patients, GNB 
were more common than GPC (81% v 19%, 
respectively; Table 3). Table 4 describes antibi-
otic susceptibility.
Most of the patients (n = 105 [64%]) had pe-
ripheral venous catheters, 45 (27%) had short-
term CVCs, and 14 (9%) had implantable ports. 
There was no statistical difference in terms of 
the BSIs detected and the type of venous cath-
eter inserted or the site of insertion (χ2 P = .27); 
however, in patients with CVCs, GNB are the 
prevalent microorganisms.
We found that BSIs occurred more frequently in 
patients with GI tumors; 93 patients (57%) had 
gastric cancer, colorectal cancer, or no colorectal 
carcinomas, and 15 (9%) had head and neck 
carcinomas (Table 5). Mortality rate at 30 days 
remained stable during the observational period, 
being on average 30%.
DISCUSSION
Little information has been reported about BSIs 
in hospitalized patients with solid tumors world-
wide. As far as we know, there are no published 
data for either Costa Rica or Central America, 
and even less is known regarding the epidemi-
ology and mortality of BSIs in our region. Most 
of the data on BSIs have been extrapolated from 
studies on hematologic malignancies in Europe 
and the United States.10-12
One interesting finding is that 14% of hospital-
ized patients with solid tumors in Mexico Hos-
pital developed a BSI, ranging from 1.2 to 1.6 
cases per 1,000 admissions of patients with solid 
malignancies per year. In the United States, the 
incidence of sepsis in patients with cancer in 
this setting is about 16.4 (including hematology 
patients); in the United Kingdom, 3.6 per 1,000 
admissions per year; and in Spain, 0.95 per 
1,000 admissions per year13-15; thus, the num-
ber of epidemiologic events in our population is 
similar to that in Spain.
GNB were by far the most frequent causative 
agents isolated in BSIs in our patients (78% of 
the episodes). This was statistically significant 
when compared with GPC (P = .029). In the 
last two decades, GPC were the leading cause 
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Table 3. Bacterial Pathogens Isolated in BSIs
Microorganism
Isolates No. of BSIs in  
Patients With  
Febrile NeutropeniaNo. %
Escherichia coli 35 21.3 6
Klebsiella pneumoniae 35 21.3 8
Pseudomonas aeruginosa 25 15.2 7
Staphylococcus aureus 16 9.8 4
Staphylococcus epidermidis 9 5.5 2
Enterobacter cloacae 7 4.3 1
Serratia marcescens 7 4.3 1
Enterobacter aerogenes 5 3.0 0
Proteus mirabilis 4 2.4 2
Enterococcus faecalis 3 1.8 1
Acinetobacter baummanni 2 1.2 1
Citrobacter freundii 2 1.2 0
Stenotrophomonas maltophilia 2 1.2 0
Streptococcus gallolyticus 2 1.2 0
Citrobacter koseri 1 0.6 0
Aeromonas hydrophila 1 0.6 0
Enterococcus gallinarum 1 0.6 0
Moraxela group 1 0.6 0
Staphylococcus haemolyticus 1 0.6 0
Streptococcus gordonii 1 0.6 0
Streptococcus group c 1 0.6 0
Streptococcus pyogenes 1 0.6 0
Unknown 2 1.2 0
Total 164 100 33
Abbreviation: BSI, bloodstream infection.
Table 4. Antibiotic susceptibility
Antibiotic susceptibility profile No. %
Extended-spectrum beta-
lactamase among all GNB
27 21
Methicillin-resistant 
Staphylococcus aureus 
among GPB
19 50
Metallo beta-lactamase 
producers
2 1.5
Vancomycin-resistant,  
linezolid-susceptible
1 2.0
Not performed 2 1.2
Abbreviations: GNB, gram-negative bacilli; GPB, gram-positive 
bacilli.
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of BSIs in patients with cancer (including those 
with hematologic malignancies), but several in-
stitutions have recently reported that up to 65% 
of BSIs are the result of GNB.3 We have observed 
the same epidemiologic trend, with K. pneumo-
niae, E. coli, and P. aeruginosa being the main 
microorganisms involved in BSIs, and the same 
microorganisms that are responsible for bactere-
mia in other series reported in Europe.4,12,16 This 
high incidence of GNB can be attributed to the 
fact that most of the bacteremias occur after sur-
gery in the GI tract.17 In our series, we found that 
about 20% of the BSIs occurred in neutropenic 
patients, with gram-negative rods being the most 
commonly isolated, in concordance with other 
reports mainly from developing countries.18 In 
terms of susceptibility profile, 68% of the bacte-
ria were susceptible to the majority of antibiotics 
tested, and 21% expressed extended-spectrum 
beta-lactamase; E. coli and K. pneumoniae iso-
lates that produced extended-spectrum beta- 
lactamase ranged from 12% to 75% (mean, 
35%) in patients with cancer (including those 
with and without febrile neutropenia).19
Of the 59 patients with bacteremia and CVCs, 43 
(73%) experienced BSIs associated with GNB, 
which is concerning because gram-positive micro-
organisms are more frequently described as the 
causative agents in catheter-related bacteremia.20 
This increased prevalence of gram-negative 
bacteria could be attributed to inadequate han-
dling of CVCs by health care personnel. There 
was no statistical difference between type of 
catheter and the site of insertion, which means 
that regardless of the type of CVC (long-term or 
short-term), the incidence of catheter-related 
BSIs was the same and was mainly due to GNB. 
This information is particularly useful for prescrib-
ing empirical antibiotics. In our case, we should 
start antibiotics with an anti-GNB spectrum as 
first-line therapy, either including or omitting 
anti-GPC treatment.
With respect to tumor site, 57% of BSI episodes 
occurred in GI cancers, followed by head and 
neck cancers (9.2%) and genitourinary cancers 
(8.5%). This distribution may explain the high 
incidence of BSIs caused by GNB, because this 
population underwent surgery, and bacteria may 
have translocated from the GI tract. In other 
studies, gram-negative BSIs were reported in 
about 62% of the patients in this setting.17
Our mortality rate at 30 days was about 30%, 
and the mortality rate ranged from 16% to 30% 
in the United States, Brazil, and Spain.3,11 On the 
basis of those data, we had an acceptable and 
stable mortality rate during the observation time 
period.
Our study has some limitations. First, it was 
based on a retrospective database, and we can-
not exclude any selection bias. In addition, we 
cannot rule out any misclassification bias result-
ing from the retrospective collection of the data. 
Furthermore, our findings are based on a single 
institution experience, and the external validity 
of our research could be limited. Despite these 
caveats, we think our findings increase the 
knowledge about this important topic in our 
area.
In conclusion, limited data are available in Lat-
in America regarding BSIs in patients with solid 
malignancies. With this study, we were able to 
determine that GNB are by far the most frequent 
cause of BSIs in our population. Neutropenic 
patients with solid tumors are infected mainly by 
GNB. BSIs are more frequent in patients with GI 
tumors. In our environment, infected CVCs are 
due to GNB. Mortality and antibiotic suscepti-
bility remain stable and acceptable in this Latin 
American population. Understanding the epide-
miology in our area can improve and optimize 
first-line antimicrobial therapies.
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Table 5. Frequency of BSIs According to Solid Malignancy
Solid Tumor Histology No. %
Gastric adenocarcinomas 43 26.21
Noncolorectal GI 27 16.46
Colorectal adenocarcinomas 23 14.02
Head and neck carcinomas 15 9.15
Genitourinary cancer 14 8.54
Sarcomas (osteosarcomas and soft tissue 
sarcomas)
14 8.54
Breast cancer 8 4.88
Non–small-cell lung cancer 7 4.30
Gynecologic malignancies 6 3.60
Other solid malignancies 7 4.30
Total 164 100.00
Abbreviation: BSI, bloodstream infection.
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